Why the study?
Does extrinsic pathway inhibitor (EPI) contribute to the anticoagulant effect of heparin in human blood?
Does extrinsic pathway inhibitor (EPI) contribute to the anticoagulant effect of heparin in human blood?
Extrinsic pathway inhibitor (EPI) plays a significant role alongside antithrombin in mediating the anticoagulant effect of heparin in human blood.
Answers are grounded in this paper and cite their sources.
Supports EPI contribution to heparin's effect in animal blood; leaves open relevance to human anticoagulation.
Heparinization of blood inhibited the generation of fibrinopeptide A (FPA) after addition of thromboplastin (TP). Heparinization was more effective when performed in vivo than in vitro; the amounts of FPA at 60 s incubation were 8% and 32%, respectively, of control values in nonheparinized blood. When monospecific, neutralizing IgG against extrinsic pathway inhibitor (anti-EPI) were added to heparinized blood prior to TP, the amount of FPA increased to 65%. When monospecific IgG blocking antithrombin (anti-AT) was used, the amount of FPA increased to values similar to those in nonheparinized blood. When anti-AT and anti-EPI were both added to heparinized blood, FPA was generated about 25% faster than in normal blood. These results show that EPI contributes significantly to the anticoagulant effect of heparin in human blood.
No takes yet. Share an insight, caveat, or question.
Abildgaard et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: